Johnson v. Eli Lilly and Co.

689 F. Supp. 170, 1988 U.S. Dist. LEXIS 7840, 1988 WL 77624
CourtDistrict Court, W.D. New York
DecidedJuly 27, 1988
DocketCIV-87-1080T
StatusPublished
Cited by8 cases

This text of 689 F. Supp. 170 (Johnson v. Eli Lilly and Co.) is published on Counsel Stack Legal Research, covering District Court, W.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Johnson v. Eli Lilly and Co., 689 F. Supp. 170, 1988 U.S. Dist. LEXIS 7840, 1988 WL 77624 (W.D.N.Y. 1988).

Opinion

DECISION AND ORDER

TELESCA, District Judge.

INTRODUCTION

Plaintiffs Carol Johnson and her husband, Larry Johnson (“the Johnsons”) commenced this action in New York State Supreme Court alleging that Carol Johnson’s mother ingested diethylstilbestrol (“DES”) manufactured by Eli Lilly in 1952, and that Carol Johnson has been injured as a result. Eli Lilly removed the action to this Court on the basis of diversity jurisdiction.

The Johnsons now move for partial summary judgment, contending that Eli Lilly is collaterally estopped from disputing certain facts based on the special jury verdict returned in a prior DES case against Eli Lilly. Defendants cross-move for summary judgment dismissing the complaint, contending that plaintiffs are barred from bringing this action under the doctrine of res judicata. I find that plaintiffs are barred from bringing this action under the doctrines of res judicata and collateral estoppel, and, therefore, grant defendants’ motion to dismiss the complaint.

PACTS

Plaintiffs allege that Carol Johnson’s mother, Elizabeth Philbin, took DES in 1952 while she was pregnant with Carol Johnson. The prescription written by Mrs. Philbin’s physician called for a five milligram dose of an Eli Lilly product known as Enseals Stilbestrol. “Enseals” is a trade-name used exclusively by Eli Lilly.

Carol Johnson has been diagnosed as having carcinoma in situ of the cervix, vaginal adenosis with focal dysplasis and typical DES changes in the cervix. She entered the Genesee Hospital on July 6, 1981, and received a total abdominal hysterectomy.

Prior Litigation

On February 23,1983, the Johnsons commenced a products liability action against Eli Lilly in the United States District Court for the Western District of Pennsylvania based on Mrs. Philbin’s ingestion of DES and Carol Johnson’s development of cancer. (“Johnson I”) In an Order dated September 19, 1983, the court granted Eli Lilly’s motion to dismiss, finding that the action was barred by the New York statute of limitations which accrued at the time Mrs. Philbin ingested the DES. Johnson v. Eli Lilly and Co., 577 F.Supp. 174 (W.D.Pa. *172 1983), aff'd, 738 F.2d 422 (3d Cir.1984), cert. denied, 469 U.S. 857, 105 S.Ct. 184, 83 L.Ed.2d 118 (1984).

On December 13, 1986, the Johnsons commenced a second action in the court of Common Pleas for Allegheny County, Pennsylvania. (“Johnson II”) The case was removed on January 12, 1987 to the United States District Court for the Western District of Pennsylvania pursuant to 28 U.S.C. § 1441. The Johnsons subsequently moved for partial summary judgment, seeking to collaterally estop Eli Lilly from litigating certain issues based upon the verdict in Bichler v. Eli Lilly and Co., Index No. 15600/74 (N.Y.Sup.Ct. Bronx County, July 16, 1979), aff'd, 79 A.D.2d 317, 436 N.Y.S.2d 625 (1st Dept.1981), aff'd, 55 N.Y.2d 571, 450 N.Y.S.2d 776, 436 N.E.2d 182 (1982). Eli Lilly cross-moved for dismissal on statute of limitations and res judicata grounds.

In a Memorandum Decision and Order dated October 28, 1987, the court denied the Johnsons’ motion for summary judgment and granted Eli Lilly’s motion to dismiss. The court held that the suit was barred by res judicata because the dismissal of Johnson I constituted a decision on the merits. Applying Pennsylvania’s borrowing statute and the Pennsylvania accrual date, the judge further found that the suit was barred by the Pennsylvania statute of limitations. However, the court noted that it made no judgment as to whether the New York revival statute served to revive Johnson I because no formal motion requesting such relief had been filed. The court then granted Eli Lilly’s motion for summary judgment without prejudice to the Johnsons filing a motion to revive Johnson I.

While awaiting the decision in Johnson II, the Johnsons commenced the present action, (“Johnson III”) in New York State Supreme Court. The action was removed to this Court under diversity jurisdiction pursuant to 28 U.S.C. § 1441.

DISCUSSION

Eli Lilly contends that the Johnsons are barred by the principles of res judicata from bringing the current action because of the adverse decisions in Johnson I and Johnson II. I will address the res judicata effects of each of these decisions in turn.

Choice of Law

Johnson I and Johnson II were decisions by federal courts pursuant to diversity jurisdiction. While federal law clearly applies to determine the preclusive effect of a prior federal question judgment, there is a split of authority concerning whether state or federal law determines the res judicata and collateral estoppel effects of a prior diversity judgment. Those courts applying federal preclusion law have emphasized that the rules of claim and issue preclusion define the finality of the federal judgment and are designed to protect that judgment. See, Petromanagement Corp. v. Acme-Thomas Joint Venture, 835 F.2d 1329, 1333 (10th Cir.1988); Harnett v. Billman, 800 F.2d 1308, 1312-13 (4th Cir.1986), cert. denied, — U.S.-, 107 S.Ct. 1571, 94 L.Ed.2d 763 (1987); Aerojet-General Corp. v. Askew, 511 F.2d 710, 716-17 (5th Cir.), cert. denied, 423 U.S. 908, 96 S.Ct. 210, 46 L.Ed.2d 137 (1975); Silcox v. United Trucking Service, Inc., 687 F.2d 848, 852 (6th Cir.1982); Precision Air Parts, Inc. v. Avco Corp., 736 F.2d 1499, 1503 (11th Cir.1984), cert. denied, 469 U.S. 1191, 105 S.Ct. 966, 83 L.Ed.2d 970 (1985). In contrast, other courts have determined that preclusion law is substantive, and that the doctrine of Erie Railroad Co. v. Tomykins, 304 U.S. 64, 58 S.Ct. 817, 82 L.Ed. 1188 (1938) mandates that state preclusion law be applied in diversity actions. See, Answering Service, Inc. v. Egan, 728 F.2d 1500, 1505-06 (D.C.Cir.1984); Costantini v. Trans World Airlines, 681 F.2d 1199, 1201 (9th Cir.), cert. denied, 459 U.S. 1087, 103 S.Ct. 570, 74 L.Ed.2d 932 (1982); Iowa Electric Light & Power Co. v. Mobile Aerial Towers, Inc., 723 F.2d 50, 52 (8th Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

B-S Steel of Kansas, Inc. v. Texas Industries, Inc.
327 F. Supp. 2d 1252 (D. Kansas, 2004)
Aerogroup International, Inc. v. Shoe Show, Inc.
966 F. Supp. 175 (W.D. New York, 1997)
Prudential Securities Inc. v. Arain
930 F. Supp. 151 (S.D. New York, 1996)
B.N.E. Swedbank, S.A. v. Banker
791 F. Supp. 1002 (S.D. New York, 1992)
Carlin v. Gold Hawk Joint Venture
778 F. Supp. 686 (S.D. New York, 1991)
Phoenix Canada Oil Co., Ltd. v. Texaco Inc.
749 F. Supp. 525 (S.D. New York, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
689 F. Supp. 170, 1988 U.S. Dist. LEXIS 7840, 1988 WL 77624, Counsel Stack Legal Research, https://law.counselstack.com/opinion/johnson-v-eli-lilly-and-co-nywd-1988.